Author Archives: Kyra Baricaua

VitroGel®-Enhanced 3D Culture Models Reveal the Potential of Basroparib in Overcoming MEK Inhibitor Resistance in KRAS-Mutated Colorectal Cancer

VitroGel® supports 3D spheroid models for evaluating basroparib’s efficacy in overcoming MEK inhibitor resistance in KRAS-mutated colorectal cancer. Hydrogel: VitroGel® 3D (Cat. No: TWG001) The study on basroparib’s role in overcoming MEK inhibitor resistance in KRAS-mutated colorectal cancer (CRC) highlights the importance of innovative in vitro models that accurately recapitulate tumor microenvironments. Using VitroGel, a […]

3D Bioprinting Paves the Way for Fertility Preservation with VitroINK®

VitroINK® provided a xeno-free, structurally supportive bioink that enabled the precise 3D bioprinting of a functional testis model, facilitating cell viability, maturation, and in vitro spermatogenesis research. Fertility preservation following pediatric cancer therapy has become a critical area of research, as over 80% of childhood cancer survivors reach adulthood, yet up to 66% of male […]

Scaffold-Free 3D Adipose Tissue Organoids: Unlocking Obesity Research with VitroGel® 3D

VitroGel® 3D provided a scaffold-free yet supportive matrix that stabilized adipose organoids for imaging and analysis, enhancing the reliability of in vitro obesity research. Hydrogel:VitroGel® 3D (Cat. No: TWG001) Obesity and metabolic diseases remain urgent global health challenges, yet studying human adipose tissue in vitro is complicated by the limitations of 2D cultures and scaffold-based […]

Advancing Borderline Ovarian Tumor Research: Precision Viability Assessment in Patient-Derived Organoid Models

Biomarker Cyto3D® Live-Dead Assay Kit (Cat. No: BM01) The study explores the application of tumor organoid technology in borderline ovarian tumors (BOT), a category of tumors with limited treatment options and resistance to conventional chemotherapy. Researchers established patient-derived organoids (PDOs) to model BOT and evaluate potential therapeutic compounds, particularly Bractoppin, a BRCA1 carboxy-terminal domain (BRCT) […]

3D Organoids and Talniflumate: A Powerful Duo Against Pancreatic Cancer

Hydrogel: VitroGel® ORGANOID 3  (Cat. No: VHM04-3) Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with limited treatment options and poor patient survival rates. A major challenge in treating PDAC is the tumor’s ability to create a protective barrier of mucins, which shields cancer cells from immune attacks and reduces the effectiveness of […]

Revolutionizing Cancer Research: A Patient-Derived Platform to Model Tumor-Immune Interactions

BiomarkerCyto3D® Live-Dead Assay Kit (Cat. No: BM01) Cancer research has long been challenged by the complexity of tumor-immune interactions. Traditional 2D cell cultures and animal models often fail to capture the intricate tumor microenvironment (TME), limiting their relevance to human biology. Patient-derived precision-cut tumor slices (PCTS) offer a promising solution by preserving the tumor’s architecture […]

Game Changer for Lymphoma Therapy Screening

VitroGel® RGD played a key role in preserving tumor architecture for effective drug testing in lymphoma research. Hydrogel:VitroGel® RGD (Cat. No: TWG003) VitroGel® played a The fight against cancer, particularly B-cell lymphomas, is challenged by the complexity of tumor microenvironments and the need for personalized treatment strategies. Traditional models such as cell lines and xenografts […]

Prolonged Dexamethasone Delivery Using VitroGel® for Protection Against Cisplatin-Induced Ototoxicity

VitroGel® significantly enhanced the delivery of dexamethasone to the inner ear, providing controlled release and improved protection against cisplatin-induced hearing loss. Hydrogel: VitroGel® RGD (Cat. No: TWG003) VitroGel® played a crucial role in the study by enhancing the local delivery of dexamethasone (Dexa) to the inner ear. It facilitated a controlled and prolonged release of […]